Source: International Congress 2019 – Future of cystic fibrosis care: insights from the Lancet Commission
Disease area: -



Rating:

Share or cite this content

Citations should be made in the following way:
M. Mall (Berlin, Germany). Novel therapeutics for CF. International Congress 2019 – Future of cystic fibrosis care: insights from the Lancet Commission

Member's Comments

No comment yet.

Related content which might interest you: Novel therapeutics for cystic fibrosis Source: ERS Webinar 2020: Novel therapeutics for cystic fibrosis Year: 2020 Novel targets and emerging therapies in MPM Source: ERS Skills course: Multi-disciplinary care in thoracic oncology Year: 2019 Proteases as tools for diagnosis and novel therapeutics Source: ERS Research Seminar 2015 Year: 2015 Novel treatments for IPF Source: International Congress 2014 – ERS/NEJM joint lunchtime session "The changing landscape of idiopathic pulmonary fibrosis (IPF)" Year: 2014 Pathophysiology of CF and CFTR directed therapies Source: ERS course 2015 Year: 2015 Targeting mucus as a new therapeutic avenue? Source: Annual Congress 2011 - Mucus in airway diseases: bad or good partner? Year: 2011 Late Breaking Abstract - Anti-inflammatory activity of novel transtilbene sulfonamide analogues as potential novel therapeutic agents for inflammatory lung disease Source: International Congress 2019 – COPD treatment: cardiovascular, oxygen and vaccination studies Year: 2019 Clinical implications and novel therapies Source: International Congress 2018 – Accelerated ageing in lungs Year: 2018 From anti-PD1/L1 inhibitors to new immunotherapies Source: New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine Year: 2019 Developmental control of CFTR: from bioinformatics to novel therapeutic approaches Source: Eur Respir J 2015; 45: 18-20 Year: 2015 CFTR targeted therapies: recent advances in cystic fibrosis and possibilities in other diseases of the airways Source: Eur Respir Rev, 29 (156) 190068; 10.1183/16000617.0068-2019 Year: 2020 Pathophysiology and potential future therapeutic targets using preclinical models of COVID-19 Source: ERJ Open Res, 6 (4) 00405-2020; 10.1183/23120541.00405-2020 Year: 2020 Novel NTM treatments and approaches, repurposed to bacteriophages Source: Virtual Congress 2021 – New insights into nontuberculous mycobacteria disease: from diagnosis to treatment Year: 2021 Genomically-guided therapies: a new era for cystic fibrosis Source: Virtual Congress 2020 – European Reference Network for rare lung diseases (ERN-LUNG): acting for improved cross-border management of rare diseases Year: 2020 Human translational medicine in ILD: the promise of new drugs Source: Research Seminar 2014 - Human translational medicine: a key bridge for the development of new drugs for severe asthma, COPD and ILD Year: 2014